OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Help
Advanced
Search
15
Results
Show all
Save search
Copy query
Show results for
Unknown
(15)
Publication Date
Release Date
2022
(5)
2021
(4)
2020
(2)
2023
(1)
2019
(1)
2015
(1)
2014
(1)
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
Developing an Intranet-Based Lymphedema Dashboard for Breast Cancer Multidisciplinary Teams: Design Research Study.
Not available
S-EPMC7201315
|
biostudies-literature
Cite
Multi-sensory Gamma Stimulation Ameliorates Alzheimer's-Associated Pathology and Improves Cognition.
Not available
S-EPMC6774262
|
biostudies-literature
Cite
Dexamethasone in Hospitalized Patients with Covid-19.
Not available
S-EPMC7383595
|
biostudies-literature
Cite
2014 CUA Abstracts
Not available
S-EPMC4095672
|
biostudies-literature
Cite
Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico.
Not available
S-EPMC8693692
|
biostudies-literature
Cite
Effect of Hydroxychloroquine in Hospitalized Patients with Covid-19.
Not available
S-EPMC7556338
|
biostudies-literature
Cite
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC8084355
|
biostudies-literature
Cite
Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
Not available
S-EPMC9333998
|
biostudies-literature
Cite
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC7884931
|
biostudies-literature
Cite
Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial.
Not available
S-EPMC8121538
|
biostudies-literature
Cite
Previous
page
1 / 2
You're on page
1
page
2
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets